Skip to main content

Table 1 Summary of the clinical information of the 15 PC patients who participated in this study

From: TRAIL-coated leukocytes to kill circulating tumor cells in the flowing blood from prostate cancer patients

Patient Characteristics  
Total, N 15
Age, yr, median (range) 62 (49–73)
PSA value at diagnosis, ng/mL, median (range) 5.9 (1.04–29.48)
Biopsy stage, N (%)
 1c 11 (73%)
 1a 1 (7%)
 2b 3 (20%)
Biopsy Gleason Grade Group, N (%)  
 Grade Group 1 = 3 + 3 3 (20%)
 Grade Group 2 = 3 + 4 6 (40%)
 Grade Group 3 = 4 + 3 4 (27%)
 Grade Group 4 = 4 + 4 2 (13%)
Surgery stage, N (%)
 2a 7 (47%)
 3a 7 (47%)
 3b 1 (6%)
Surgery Gleason score, N (%)
 Grade Group 2 = 3 + 4 10 (67%)
 Grade Group 3 = 4 + 3 4 (27%)
 Grade Group 5 = 4 + 5 1 (6%)
Nodes, N (%)
 Positive 1 (7%)
 Negative 12 (80%)
 Cannot access 3 (13%)
Surgical margins, N (%)
 Positive 3 (20%)
 Negative 12 (80%)
Adjuvant therapy, N (%)
 ADT 2 (13%)
 Radiation 1 (7%)
Cancer recurrence, N (%)
 Salvage treatment 1 (7%)
 Biochemical recurrence 1 (7%)